Compare CG & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CG | DGX |
|---|---|---|
| Founded | 1987 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6B | 19.4B |
| IPO Year | 2012 | 1996 |
| Metric | CG | DGX |
|---|---|---|
| Price | $65.82 | $189.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | $67.54 | ★ $196.69 |
| AVG Volume (30 Days) | ★ 2.0M | 897.8K |
| Earning Date | 02-06-2026 | 02-10-2026 |
| Dividend Yield | ★ 2.12% | 1.68% |
| EPS Growth | ★ 445.01 | 14.49 |
| EPS | 1.78 | ★ 8.51 |
| Revenue | $3,208,300,000.00 | ★ $10,850,000,000.00 |
| Revenue This Year | N/A | $12.37 |
| Revenue Next Year | $22.77 | $3.54 |
| P/E Ratio | $37.11 | ★ $22.35 |
| Revenue Growth | N/A | ★ 13.74 |
| 52 Week Low | $33.02 | $148.70 |
| 52 Week High | $69.85 | $197.55 |
| Indicator | CG | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 67.39 | 65.88 |
| Support Level | $63.75 | $173.51 |
| Resistance Level | $67.30 | $190.99 |
| Average True Range (ATR) | 1.71 | 3.64 |
| MACD | 0.16 | 1.88 |
| Stochastic Oscillator | 82.26 | 91.65 |
Carlyle Group is one of the world's largest alternative-asset managers, with $474.1 billion in total AUM, including $332.0 billion in fee-earning AUM, at the end of September 2025. The company has three core business segments: global private equity, which includes its private equity, real estate, infrastructure, and natural resources offerings (with $163.5 billion in total AUM and $101.1 billion in fee-earning AUM), global credit ($208.5 billion/$167.2 billion), and investment/fund solutions, known as Carlyle AlphInvest ($102.1 billion/$63.7 billion). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 3,100 active carry fund investors from 87 countries.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.